Rozanolixizumab long-term extension in persistent or chronic primary immune thrombocytopenia

Open-label, single-arm trial of rozanolixizumab in immune thrombocytopenia (ITP), sponsored by UCB. Primary endpoints: Occurrence of treatment-emergent adverse events and Occurrence of treatment-emergent adverse events leading to withdrawal of rozanolixizumab. Started Aug 2021; status: active, not recruiting.